[18] INNOSPHERE OVERVIEW

Ehab Shakour¹, ¹ Innosphere ABSTRACT TEMPLATE for Company Presentations

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

Investment Rational

InnoSphere is developing innovative medical devices for treating cognitive disorders, focusing on ADHD. InnoSphere's unique patent pending technologies enable treating cognitive disorders at the home of the users accurately and safely, without pharmaceutical drugs and side effects.

Business Strategy

The university of Oxford, King's College of London and the Normal University of Beijing have already approved purchasing our research devices, which we will sell to research institutes and enable them to conduct unique cutting-edge neuroscience research that was not facilitated until now in the brain stimulation world. For the home use device, we plan to sell the devices themselves through medical device distributors at relatively low margins, and sell the treatment sessions through our online platform at high margins.

Core Technology

We have developed unique stimulation electrodes, that facilitate convenient and accurate brain stimulation, for research and clinical use. Additionally, we have developed an electrode emulation technology for delivering accurate brain stimulation in home setting.

Product Profile/Pipeline

After obtaining the CE mark on our research device, we have started sales to top tier universities in Europe, and towards engaging the US research market. We are continuing the development of our technologies for finalizing the home-use product for treating ADHD in a home setting by non-experts.

o What's Next?

These days, we are conducting clinical trials at Hadassah Medical Center in Jerusalem, using unique proprietary protocols with 60 children suffering from ADHD, in collaboration with the University of Oxford and Yale University.

We are currently towards round A funding, aimed to support further developing our technology towards home-used systems, and expanding our clinical activities for achieving regulatory approvals